<DOC>
	<DOCNO>NCT01627782</DOCNO>
	<brief_summary>The purpose study explore optimal dose frequency ketamine patient treatment-resistant depression ( TRD ) .</brief_summary>
	<brief_title>A Study Ketamine Patients With Treatment-resistant Depression</brief_title>
	<detailed_description>This double-blind ( patient study personnel know identity administer treatment ) , randomize ( drug assign chance ) , placebo-controlled ( placebo substance appear identical treatment active ingredient ) , parallel arm study ( group patient treat time ) . The study consist screen phase 4 week , 4-week double-blind treatment phase ( Day 1 Day 29 ) , 3-week post treatment ( follow ) phase . In double-blind phase , patient receive 4 week either intravenous ( IV ) infusion placebo ( 2 3 time weekly ) IV infusion ketamine ( 2 3 time weekly ) . The total study duration patient maximum 13 week .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Be medically stable basis clinical laboratory test perform screen Meet diagnostic criterion recurrent major depressive disorder ( MDD ) , without psychotic feature Have history inadequate response , ie treatment successful , least 1 antidepressant Have Inventory Depressive SymptomsClinician rat , 30 item ( IDSC30 ) total score &gt; = 40 screen predose Day 1 Inpatient agree admit clinic dose day Has uncontrolled hypertension Has history , current sign symptom disease , infection condition opinion investigator , would make participation best interest ( eg , compromise wellbeing ) patient could prevent , limit , confound protocolspecified assessment Has know allergy , hypersensitivity , intolerance ketamine excipients Is unable read understand consent form patient report outcome , complete studyrelated procedure , and/or communicate study staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>Treatment-resistant depression</keyword>
	<keyword>Ketamine</keyword>
</DOC>